Compugen Asset Resilience Ratio
Compugen asset resilience ratio. Compugen (CGEN) has an Asset Resilience Ratio of 83.77% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Compugen (CGEN) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Compugen (2001–2025)
Asset resilience ratio of Compugen from 2001 to 2025. This chart shows how Compugen's Asset Resilience Ratio has changed over time. Read Compugen total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Compugen's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CGEN total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA115.02 Million | 83.77% |
| Total Liquid Assets | ILA115.02 Million | 83.77% |
Asset Resilience Insights
- Very High Liquidity: Compugen maintains exceptional liquid asset reserves at 83.77% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Compugen Industry Peers by Asset Resilience Ratio
Compare Compugen's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Compugen Asset Resilience Ratio by Year (2001–2025)
Compugen asset resilience ratio by year from 2001 to 2025. The table below shows the annual Asset Resilience Ratio data for Compugen.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.09% | ILA55.04 Million ≈ $147.57K |
ILA156.87 Million ≈ $420.57K |
-38.85pp |
| 2024-12-31 | 73.94% | ILA85.03 Million ≈ $227.95K |
ILA115.00 Million ≈ $308.30K |
+43.61pp |
| 2023-12-31 | 30.33% | ILA36.80 Million ≈ $98.65K |
ILA121.33 Million ≈ $325.29K |
-46.43pp |
| 2022-12-31 | 76.76% | ILA72.29 Million ≈ $193.80K |
ILA94.18 Million ≈ $252.48K |
-5.90pp |
| 2021-12-31 | 82.66% | ILA109.25 Million ≈ $292.89K |
ILA132.16 Million ≈ $354.32K |
-1.65pp |
| 2020-12-31 | 84.32% | ILA116.62 Million ≈ $312.66K |
ILA138.32 Million ≈ $370.82K |
+21.00pp |
| 2019-12-31 | 63.31% | ILA34.04 Million ≈ $91.26K |
ILA53.76 Million ≈ $144.14K |
-10.41pp |
| 2018-12-31 | 73.73% | ILA39.21 Million ≈ $105.12K |
ILA53.18 Million ≈ $142.57K |
+63.62pp |
| 2017-12-31 | 10.11% | ILA3.92 Million ≈ $10.50K |
ILA38.75 Million ≈ $103.88K |
-61.33pp |
| 2016-12-31 | 71.44% | ILA50.83 Million ≈ $136.26K |
ILA71.14 Million ≈ $190.72K |
+71.02pp |
| 2015-12-31 | 0.43% | ILA426.00K ≈ $1.14K |
ILA99.31 Million ≈ $266.24K |
-0.49pp |
| 2014-12-31 | 0.92% | ILA1.05 Million ≈ $2.83K |
ILA114.84 Million ≈ $307.90K |
-7.13pp |
| 2013-12-31 | 8.05% | ILA4.57 Million ≈ $12.24K |
ILA56.71 Million ≈ $152.04K |
-9.92pp |
| 2012-12-31 | 17.97% | ILA5.20 Million ≈ $13.93K |
ILA28.91 Million ≈ $77.50K |
-38.85pp |
| 2011-12-31 | 56.82% | ILA16.52 Million ≈ $44.30K |
ILA29.08 Million ≈ $77.97K |
+16.99pp |
| 2010-12-31 | 39.84% | ILA14.52 Million ≈ $38.94K |
ILA36.46 Million ≈ $97.74K |
-1.70pp |
| 2008-12-31 | 41.53% | ILA5.92 Million ≈ $15.86K |
ILA14.24 Million ≈ $38.19K |
-22.09pp |
| 2007-12-31 | 63.62% | ILA13.78 Million ≈ $36.95K |
ILA21.67 Million ≈ $58.09K |
+1.55pp |
| 2006-12-31 | 62.07% | ILA19.15 Million ≈ $51.35K |
ILA30.86 Million ≈ $82.72K |
-9.79pp |
| 2005-12-31 | 71.86% | ILA30.26 Million ≈ $81.12K |
ILA42.11 Million ≈ $112.88K |
+42.58pp |
| 2004-12-31 | 29.28% | ILA16.21 Million ≈ $43.45K |
ILA55.35 Million ≈ $148.40K |
+16.25pp |
| 2003-12-31 | 13.03% | ILA8.80 Million ≈ $23.58K |
ILA67.53 Million ≈ $181.03K |
-3.69pp |
| 2002-12-31 | 16.72% | ILA12.92 Million ≈ $34.63K |
ILA77.26 Million ≈ $207.12K |
+6.13pp |
| 2001-12-31 | 10.59% | ILA9.24 Million ≈ $24.77K |
ILA87.29 Million ≈ $234.02K |
-- |
About Compugen
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical tria… Read more